Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World's First Saliva-Based Exosomal Biomarker "miR-185" as Dual Diagnostic and Therapeutic Target for Oral Cancer

Stock Information for Avalon GloboCare Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalon GloboCare Corp.

Avalon GloboCare Announces $6 Million Registered Direct Offering with Institutional Investors
Eminent M.I.T. Institute Professor, Robert S. Langer, Sc.D., Joins Avalon GloboCare's Scientific and Clinical Advisory Board
Avalon GloboCare to Host The 3rd Annual International Scientific Forum on Exosome Research and Application (ISFERA) in Beijing on July 19, 2019
Avalon GloboCare Appoints Finance Veteran Yue ''Charles'' Li to the Board of Directors
Avalon GloboCare to Present at the 31st Annual ROTH Conference on March 17-19, 2019
Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA-101, a Novel Transposon-Based, Multi-Targeted CAR-T Therapy
Avalon GloboCare Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived from Endothelial Cells
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the "Status of Cellular Therapy in the Asia Pacific Rim" Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASBMT and CIBMTR Tandem Meeting 2019

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.